Skip to main content
Premium Trial:

Request an Annual Quote

Millipore to Distribute BioTime Progenitor Cell Lines

NEW YORK (GenomeWeb News) – Millipore will be the worldwide distributor of the ACTCellerate human progenitor cell lines under a co-marketing agreement signed with BioTime subsidiary Embryome Sciences, BioTime said yesterday.

The ACTCellerate line is derived from human embryonic stem cells but not fully differentiated into specific cell types and are used in drug discovery, research, and development. BioTime said that the cell lines are generated using a two-step multiplex process that rapidly isolates and purifies progenitor cells from different lineages.

Millipore will initially offer six novel progenitor cell lines and optimized ESpan growth media for in vitro propagation of each cell line. The firms expect to jointly launch 35 cell lines and associated growth media over the next 12 months.

"We believe that Embryome Sciences' novel, highly-purified, and scalable progenitor lines have potential to be a significant breakthrough for the industry," Donald O'Neil, director of marketing for stem cells and cell biology at Millipore, said in a statement.

Financial and other terms of the alliance were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more